We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness and Safety of Mitral Valve Repair With the NeoChord DS1000 Artificial Chordae Delivery System Versus Conventional Surgery in Patients With Severe Primary Mitral Regurgitation Due to Isolated Leaflet Prolapse (MITRACHORD)

This study is not yet open for participant recruitment.
Verified July 2016 by Hospices Civils de Lyon
Sponsor:
ClinicalTrials.gov Identifier:
NCT02829749
First Posted: July 12, 2016
Last Update Posted: July 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Hospices Civils de Lyon
  Purpose
The main objective is to assess the effectiveness and safety of the NeoChord DS1000 repair technique as compared with conventional open-heart on-pump mitral valve surgery in patients with severe primary mitral regurgitation.

Condition Intervention
Cardiovascular Diseases Device: NeoChord beating heart mitral valve implantation Procedure: Control

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A European, Multicenter, Randomized Study Comparing the Effectiveness and Safety of Mitral Valve Repair With the NeoChord DS1000 Artificial Chordae Delivery System Versus Conventional Surgery in Patients With Severe Primary Mitral Regurgitation Due to Isolated Leaflet Prolapse

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • Combined incidence of Death from any cause, redo surgery for valve dysfunction, and moderate-severe (3+) or severe (4+) mitral regurgitation [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Proportion of patients with any major adverse events [ Time Frame: 30 days ]
    Major adverse events defined by death all cause, Post-operative myocardial infarction, Reoperation for failed surgical repair or valve replacement, Any reoperation or intervention for adverse events (Bleeding…), stoke, renal failure, wound infection, septicemia, ventilation > 24 hours, transfusion ≥ 2 units

  • Overall survival [ Time Frame: 12 months ]
  • Mitral valve reoperation free survival [ Time Frame: 12 months ]
  • mitral regurgitation > 2+ [ Time Frame: 12 months ]
  • Freedom from rehospitalization for heart failure [ Time Frame: 12 months ]
  • Change in functional evaluation (NYHA) [ Time Frame: 12 months ]
  • Change in functional evaluation (6 minute walk test ) [ Time Frame: 12 months ]
  • Change in quality of life score [ Time Frame: 12 months ]
    by using the EQ-5D questionnaire ( European Quality of Life-5 Dimensions) instrument

  • Number of device success [ Time Frame: 30 days ]

Estimated Enrollment: 194
Study Start Date: December 2016
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NeoChord DS1000 Artificial Chordae Delivery System
Subjects randomized to the experimental group will undergo the NeoChord implantation
Device: NeoChord beating heart mitral valve implantation
The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
Control
traditional mitral valve repair performed under cardiac arrest
Procedure: Control
traditional mitral valve repair performed under cardiac arrest

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Severe primary mitral regurgitation (grade 3+ or 4+)
  • Class I indication for MV Surgery according to ESC/EACTS and AHA/ACC guidelines:

    1. Symptomatic patients and/or
    2. LV (Left Ventricular) dysfunction : LVESD ≥45 mm and/or 30≤ LVEF ≤60%
  • Leaflet prolapse of P2 and/or A2
  • Predicted coaptation length > 4 mm
  • Candidates for surgical mitral valve repair according to heart team
  • Patient able to sign an informed consent form
  • Patient benefiting from a social insurance system or a similar system

Exclusion Criteria:

  • Asymptomatic patients with preserved LV function
  • Complex mechanism of MR (leaflet perforation, severe calcifications, commissural extension, etc)
  • Secondary MR
  • Predicted post-repair coaptation length less than 4 mm
  • Atrial fibrillation
  • Inflammatory or infective valve disease
  • Severe LV dilation (DTD > 65 mm)
  • Significant mitral annulus dilatation (D > 45 mm)
  • Surgical indication of tricuspid annulus
  • Contraindication to TEE (transesophageal echocardiographic ) or inadequate image quality
  • Need for any other concomitant cardiac procedure
  • Concurrent medical condition with a life expectancy of less than 24 months
  • Patient unable to understand the purpose of the trial
  • Patient < 18 years old
  • Participation to another trial that would interfere with this trial
  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02829749


Contacts
Contact: Jean-François OBADIA, MD 4 72 35 72 47 ext +33 jean-francois.obadia@chu-lyon.fr
Contact: Nathan MEWTON, MD 4 27 85 66 87 nathan.mewton@chu-lyon.fr

Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: Jean-François OBADIA, MD Hospices Civils de Lyon
  More Information

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT02829749     History of Changes
Other Study ID Numbers: 69HCL16_0115
First Submitted: July 4, 2016
First Posted: July 12, 2016
Last Update Posted: July 12, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Hospices Civils de Lyon:
Heart Valve Diseases
Heart failure
Heart diseases
Mitral valve insufficiency

Additional relevant MeSH terms:
Cardiovascular Diseases
Prolapse
Mitral Valve Insufficiency
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases